Some of the unpredictability of responses to PD-L1/PD-1 checkpoint blockade therapies may be due to the heterogeneity and dynamics of PD-L1 expression by tumor cells and immune cells, including dendritic cells and CD8+ T cells (34, 35). The gene discussed is CD8A; the disease is neoplasm.